脐带间充质干细胞治疗心脏扩大伴心力衰竭类心肌病病儿的效果  

CLINICAL EFFECT OF UMBILICAL CORD MESENCHYMAL STEM CELLS IN TREATMENT OF CARDIOMYOPATHY WITH CARDIOMEGALY AND HEART FAILURE IN CHILDREN

作　　者：张钰[1] 王本臻[1] 纪志娴[1] 万浩[2] 李自普[1,3] ZHANG Yu;WANG Benzhen;JI Zhixian;WAN Hao;LI Zipu(Heart Center,Women and Children＇s Hospital of Qingdao University,Qingdao 266034,China)

机构地区：[1]青岛大学附属妇女儿童医院,青岛市妇女儿童医院心脏中心,山东青岛266034 [2]青岛大学附属妇女儿童医院,青岛市妇女儿童医院儿童超声科,山东青岛266034 [3]青岛大学附属妇女儿童医院,青岛市妇女儿童医院重症医学中心,山东青岛266034

出　　处：《精准医学杂志》2018年第4期295-299,共5页Journal of Precision Medicine

基　　金：青岛市医疗卫生优秀人才培养项目资助(青卫科教字[2017]4号)

摘　　要：目的探讨人脐带间充质干细胞(hUC-MSCs)治疗心脏扩大伴心力衰竭类心肌病病儿的效果。方法心脏扩大伴心力衰竭类心肌病病儿17例,均接受hUC-MSCs治疗,分析治疗前后临床症状、体征及辅助检查结果。主要观察指标为病儿心力衰竭的症状,无症状生存时间,死亡和存活人数及左心室射血分数、左心室短轴缩短率,左心室舒张末期内径、左心室收缩末期内径和氨基末端脑钠肽前体(NT-proBNP)水平。结果 hUC-MSCs治疗后,17例病儿临床症状明显改善,活动耐力增强,13例(76.5%)病儿无症状生存;治疗后病儿左心室射血分数明显提高(P<0.05),NT-proBNP水平不同程度降低;15例(88.2%)病儿心功能不同程度好转或无恶化。细胞治疗后原发心律失常不同程度改善,生存质量改善,无死亡者。结论 hUC-MSCs治疗可改善心脏扩大伴心力衰竭的心肌病病儿的临床症状及心功能,改善生存质量。Objective To investigate the clinical effect of human umbilical cord mesenchymal stem cells（hUC-MSCs）in the treatment of cardiomyopathy with cardiomegaly and heart failure in children. Methods A total of 17 children with cardiomyopathy with cardiomegaly and heart failure were enrolled and were given the treatment with hUC-MSCs.Clinical symptoms,signs,and auxiliary examination results before and after treatment were analyzed.Major observation indices included clinical symptoms of heart failure,symptom-free survival time,numbers of deaths and survivors,left ventricular ejection fraction,left ventricular fractional shortening,left ventricular end-diastolic diameter,left ventricular end-systolic diameter,and N-terminal pro-brain natriuretic peptide（NT-proBNP）level. Results After the treatment with hUC-MSCs,all 17 children had significant improvements in clinical symptoms and activity endurance,and 13 children（76.5%）achieved symptom-free survival.After treatment,the children had a significant increase in left ventricular ejection fraction（P〈0.05）and varying degrees of reduction in NT-proBNP level（P〈0.05）.Of all children,15（88.2%）had varying degrees of improvement in cardiac function or had no deterioration.There were varying degrees of improvement in primary arrhythmia and a significant improvement in quality of life.No deaths were observed.Conclusion The treatment with hUC-MSCs can improve the clinical symptoms and cardiac function of children with cardiomyopathy with cardiomegaly and heart failure and improve their quality of life.

关 键 词：间充质基质细胞 脐带 心肌病 扩张型 心力衰竭 心脏功能试验 

分 类 号：R725.41[医药卫生—儿科]